Next day sentinel node biopsy for melanoma after lymphoscintigraphy using 99mTc-labelled nanocolloid does not adversely affect long-term outcomes
We do not find a significant effect on long-term outcomes when SLNB is performed the day after LSG with <sup>99m</sup>Tc-labelled nanocolloid tracer. We infer that tracer migration is not clinically significant within 24 h of injection based on long term clinical outcome data.
Authors
- Amit Roshan (ORCID: https://orcid.org/0000-0002-2034-2759)
- Terouz Pasha (ORCID: https://orcid.org/0000-0002-5339-8839)
- Luigi Aloj (ORCID: https://orcid.org/0000-0002-7452-4961)
- Amer Durrani (ORCID: https://orcid.org/0000-0002-6105-258X)
- Animesh Patel
- Georgios Kounidas (ORCID: https://orcid.org/0000-0002-1580-2917)
- Suzanne Murphy (ORCID: https://orcid.org/0000-0001-5589-0774)
- John Buscombe
Institutions
- Royal Free London NHS Foundation Trust (GB)
- University of Cambridge (GB)
- Cancer Research UK (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Mid Essex Hospital Services NHS Trust (GB)
Publication Details
- Journal
- Annals of Nuclear Medicine
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1007/s12149-024-01980-y
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Department of Health and Social Care
- Norgine
- NIHR Cambridge Biomedical Research Centre
- Cancer Research UK Cambridge Institute, University of Cambridge